Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: The familial atypical multiple mole melanoma-pancreatic carcinoma syndrome

Cancer

Volumn 94, Issue 1, 2002, Pages 84-96

  Lynch, Henry T ^a   Brand, Randall E ^b   Hogg, David ^c   Deters, Carolyn A ^a   Fusaro, Ramon M ^a   Lynch, Jane F ^a   Liu, Ling ^c   Knezetic, Joseph ^a   Lassam, Norman J ^c   Goggins, Michael ^d   Kern, Scott ^e  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CDKN2 genes; Familial atypical multiple mole melanoma; Genotypic heterogeneity; Malignant melanoma; Pancreatic carcinoma; Phenotypic heterogeneity

Indexed keywords

ARTICLE; CANCER RISK; DISEASE CLASSIFICATION; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA PANCREATIC CARCINOMA SYNDROME; FAMILIAL DISEASE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; AGED; DYSPLASTIC NEVUS SYNDROME; FEMALE; GENES, P16; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASTIC SYNDROMES, HEREDITARY; PANCREATIC NEOPLASMS; PEDIGREE; PHENOTYPE; POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

EID: 0036143702     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10159     Document Type: Article

References (54)

1. Cancer statistics, 2000
2. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada
3. Familial pancreatic cancer: A review
4. Kip1 protein levels independently predict outcome after breast cancer
5. Genetic susceptibility to nonpolyposis colorectal cancer
6. Pancreatic carcinoma and hereditary, nonpolyposis colorectal cancer: A family study
7. Identification of the breast cancer susceptibility gene BRCA2
8. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer
9. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene
10. Increased risk of cancer in the Peutz-Jeghers syndrome
11. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers
12. Family studies of malignant melanoma and associated cancer
13. Systemic cancer and the FAMMM syndrome
14. Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1, and BRCA2 mutations
15. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden)
16. Impact of p16 expression on surgical management of malignant melanoma and pancreatic carcinoma
17. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma
18. JNK4 allele (Asp145Cys) in a family with multiple pancreatic carcinomas
19. Abrogation of the Rb/p16 tumor suppressive pathway in virtually all pancreatic carcinomas
20. Case of fungoid disease
21. Heredity and malignant melanoma: Implications for early cancer detection
22. Familial atypical multiple mole-melanoma syndrome
23. Origin of familial malignant melanomas from heritable melanocytic lesions. "The B-K mole syndrome."
24. Familial atypical multiple mole-melanoma (FAMMM) syndrome: Segregation analysis
25. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi
26. A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: A maximum-likelihood combined linkage and association analysis in twins and their sibs
27. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families
28. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
29. Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene
30. JNK4 mutations
31. Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families
32. Family information service and hereditary cancer
33. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations
34. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families
35. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
36. Molecular technology and pancreatic cancer
37. Progression model for pancreatic cancer
38. Genetic alterations during colorectal-tumor development
39. The multistep nature of cancer
40. Cancer-susceptibility genes. Gatekeepers and caretakers
41. Clonal analysis of human colorectal tumors
42. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
43. Pancreatic duct hyperplasia and cancer
44. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer
45. Varying grades of epithelial atypia in the pancreatic ducts of humans. Classification based on morphometry and multivariate analysis and correlated with positive reactions of carcinoembryonic antigen
46. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas
47. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma
48. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations
49. Attenuated familial adenomatous polyposis (AFAP): A phenotypically and genotypically distinctive variant of FAP
50. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC
51. The international collaborative group on hereditary nonpolyposis colorectal cancer (ICG-HNPCC)
52. ICG-HNPCC. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC
53. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel